ESR1 and breast carcinoma: In ER-positive (ER+) HER2-negative (HER2-) breast cancer cells [114], elacestrant inhibits 17β-estradiol-mediated cell proliferation at concentrations that induce ERα protein degradation mediated through the proteasome pathway [115].